(HQL) Tekla Life Sciences - Overview

Sector: Financial ServicesIndustry: Asset Management | Exchange NYSE (USA) | Currency USD | Market Cap: 479m | Total Return 44.5% in 12m

Stock: Biotech, Pharma, Devices, Services, Agriculture

Total Rating 62
Risk 78
Buy Signal -0.08
Asset Management +8.1
Asset Management & Custody Banks +8.9
Market Cap: 479m
Avg Trading Vol: 1.72M USD
ATR: 2.15%
Peers RS (IBD): 81.5
Risk 5d forecast
Volatility 20.3%
Relative Tail Risk -0.45%
Reward TTM
Sharpe Ratio 1.47
Alpha 32.08
Character TTM
Beta 0.797
Beta Downside 0.776
Drawdowns 3y
Max DD 25.10%
CAGR/Max DD 0.80

Description: HQL Tekla Life Sciences March 04, 2026

HQL, or Abrdn Life Sciences Investors, is a US-based closed-end fund managed by abrdn Inc.

The fund invests globally in public equities within the life sciences sector. This includes biotechnology, pharmaceuticals, and medical equipment. The life sciences sector is characterized by extensive research and development cycles.

HQL primarily targets growth stocks of small-cap companies. Small-cap companies often present higher growth potential but also increased volatility.

Investment decisions are based on fundamental analysis, evaluating factors such as market position, management experience, technological expertise, and financial self-sufficiency or access to capital.

The fund benchmarks its performance against the NASDAQ Biotech Index and the S&P 500 Index. Further research on ValueRay can provide detailed performance analytics.

Headlines to watch out for

  • Biotechnology sector performance impacts portfolio value
  • Small-cap growth stock volatility affects returns
  • Global healthcare regulatory changes create investment risk
  • NASDAQ Biotech Index correlation influences fund performance
  • Access to capital for portfolio companies is crucial

Piotroski VR‑10 (Strict, 0-10) 3.5

Net Income: 170.9m TTM > 0 and > 6% of Revenue
FCF/TA: -0.00 > 0.02 and ΔFCF/TA -0.45 > 1.0
NWC/Revenue: 1.57% < 20% (prev -2.11%; Δ 3.68% < -1%)
CFO/TA -0.00 > 3% & CFO -2.32m > Net Income 170.9m
Net Debt (-75.5k) to EBITDA (186.1m): -0.00 < 3
Current Ratio: 1.74 > 1.5 & < 3
Outstanding Shares: last quarter (28.9m) vs 12m ago 5.56% < -2%
Gross Margin: 69.46% > 18% (prev 0.77%; Δ 6.87k% > 0.5%)
Asset Turnover: 7.06% > 50% (prev 7.59%; Δ -0.53% > 0%)
Interest Coverage Ratio: -1.41 > 6 (EBITDA TTM 186.1m / Interest Expense TTM -71.0m)

Altman Z'' 10.00

A: 0.00 (Total Current Assets 1.25m - Total Current Liabilities 721k) / Total Assets 515.4m
B: 0.15 (Retained Earnings 77.6m / Total Assets 515.4m)
C: 0.21 (EBIT TTM 99.9m / Avg Total Assets 478.7m)
D: 45.13 (Book Value of Equity 77.9m / Total Liabilities 1.73m)
Altman-Z'' Score: 49.29 = AAA

Beneish M

DSRI: 10.00 (Receivables 1.14m/113k, Revenue 33.8m/33.6m)
GMI: 1.11 (GM 69.46% / 76.83%)
AQI: none (AQ_t none / AQ_t-1 none)
SGI: 1.01 (Revenue 33.8m / 33.6m)
TATA: 0.34 (NI 170.9m - CFO -2.32m) / TA 515.4m)
Beneish M-Score: cannot calculate (missing components)

What is the price of HQL shares?

As of March 27, 2026, the stock is trading at USD 16.54 with a total of 40,294 shares traded.
Over the past week, the price has changed by +1.60%, over one month by -0.60%, over three months by -0.82% and over the past year by +44.49%.

Is HQL a buy, sell or hold?

Tekla Life Sciences has no consensus analysts rating.

What are the forecasts/targets for the HQL price?

Issuer Target Up/Down from current
Wallstreet Target Price - -
Analysts Target Price - -

HQL Fundamental Data Overview March 25, 2026

P/E Trailing = 5.7993
P/S = 247.0642
P/B = 0.9323
Revenue TTM = 33.8m USD
EBIT TTM = 99.9m USD
EBITDA TTM = 186.1m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = -75.5k USD (from netDebt column, last quarter)
Enterprise Value = 478.8m USD (478.9m + (null Debt) - CCE 75.5k)
Interest Coverage Ratio = -1.41 (Ebit TTM 99.9m / Interest Expense TTM -71.0m)
EV/FCF = -206.4x (Enterprise Value 478.8m / FCF TTM -2.32m)
FCF Yield = -0.48% (FCF TTM -2.32m / Enterprise Value 478.8m)
FCF Margin = -6.86% (FCF TTM -2.32m / Revenue TTM 33.8m)
Net Margin = 505.4% (Net Income TTM 170.9m / Revenue TTM 33.8m)
Gross Margin = 69.46% ((Revenue TTM 33.8m - Cost of Revenue TTM 10.3m) / Revenue TTM)
Gross Margin QoQ = 78.99% (prev 86.12%)
Tobins Q-Ratio = 0.93 (Enterprise Value 478.8m / Total Assets 515.4m)
Interest Expense / Debt = unknown (Interest Expense 30.7m / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 78.9m (EBIT 99.9m * (1 - 21.00%))
Current Ratio = 1.74 (Total Current Assets 1.25m / Total Current Liabilities 721k)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = -0.00 (Net Debt -75.5k / EBITDA 186.1m)
Debt / FCF = 0.03 (negative FCF - burning cash) (Net Debt -75.5k / FCF TTM -2.32m)
Total Stockholder Equity = 452.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 35.70% (Net Income 170.9m / Total Assets 515.4m)
RoE = 37.76% (Net Income TTM 170.9m / Total Stockholder Equity 452.6m)
RoCE = 19.40% (EBIT 99.9m / Capital Employed (Total Assets 515.4m - Current Liab 721k))
RoIC = 19.41% (EBIT 99.9m / (Assets 515.4m - Curr.Liab 721k - Cash 75.5k))
WACC = 8.79% (E(478.9m)/V(478.9m) * Re(8.79%) + (debt-free company))
Discount Rate = 8.79% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.74%
[DCF] Fair Price = unknown (Cash Flow -2.32m)
EPS Correlation: -2.16 | EPS CAGR: 100.2% | SUE: 2.47 | # QB: 1
Revenue Correlation: 12.68 | Revenue CAGR: -26.28% | SUE: N/A | # QB: 0

Additional Sources for HQL Stock

Fund Manager Positions: Dataroma | Stockcircle